Baseline characteristics of different second-line therapy subgroups
| Clinicopathologic variables | Total | Gem-based regimen for second-line treatment subgroup | P | Total | 5-FU-based regimen for second-line treatment subgroup | P | ||
|---|---|---|---|---|---|---|---|---|
| Combined regimen (%) | Single Gem (%) | Combined regimen (%) | Single 5-FU (%) | |||||
| n | 344 | 280 | 64 | 453 | 348 | 105 | ||
| Age (years) | ||||||||
| ≤ 63 | 173 (50.3) | 147 (52.5) | 26 (40.6) | 0.115 | 266 (58.7) | 199 (57.2) | 67 (63.8) | 0.273 |
| > 63 | 171 (49.7) | 133 (47.5) | 38 (59.4) | 187 (41.3) | 149 (42.8) | 38 (36.2) | ||
| Gender | ||||||||
| Female | 148 (43.0) | 123 (43.9) | 25 (39.1) | 0.569 | 208 (45.9) | 162 (46.6) | 46 (43.8) | 0.702 |
| Male | 196 (57.0) | 157 (56.1) | 39 (60.9) | 245 (54.1) | 186 (53.4) | 59 (56.2) | ||
| CA19-9 (U/mL) | ||||||||
| ≤ 200 | 146 (42.4) | 115 (41.1) | 31 (48.4) | 0.350 | 218 (48.1) | 171 (49.1) | 47 (44.8) | 0.500 |
| > 200 | 198 (57.6) | 165 (58.9) | 33 (51.6) | 235 (51.9) | 177 (50.9) | 58 (55.2) | ||
| Primary tumor size (cm) | ||||||||
| ≤ 4 | 182 (52.9) | 152 (54.3) | 30 (46.9) | 0.351 | 239 (52.8) | 178 (51.1) | 61 (58.1) | 0.255 |
| > 4 | 162 (47.1) | 128 (45.7) | 34 (53.1) | 214 (47.2) | 170 (48.9) | 44 (41.9) | ||
| Metastatic lesion size (cm) | ||||||||
| ≤ 4 | 194 (56.4) | 157 (56.1) | 37 (57.8) | 0.909 | 237 (52.3) | 184 (52.9) | 53 (50.5) | 0.749 |
| > 4 | 150 (43.6) | 123 (43.9) | 27 (42.2) | 216 (47.7) | 164 (47.1) | 52 (49.5) | ||
| Metastatic lesion size [mean (SD), cm] | ||||||||
| 2.94 (1.34) | 2.93 (1.31) | 2.98 (1.46) | 0.780 | 3.04 (1.25) | 3.04 (1.24) | 3.01 (1.27) | 0.806 | |
| Location | ||||||||
| Pancreas other than the pancreatic head | 116 (33.7) | 92 (32.9) | 24 (37.5) | 0.574 | 159 (35.1) | 122 (35.1) | 37 (35.2) | > 0.999 |
| Pancreatic head | 228 (66.3) | 188 (67.1) | 40 (62.5) | 294 (64.9) | 226 (64.9) | 68 (64.8) | ||
| Distant metastasis | ||||||||
| Absent | 38 (11.0) | 33 (11.8) | 5 (7.8) | 0.488 | 49 (10.8) | 41 (11.8) | 8 (7.6) | 0.306 |
| Present | 306 (89.0) | 247 (88.2) | 59 (92.2) | 404 (89.2) | 307 (88.2) | 97 (92.4) | ||
| Liver metastasis | ||||||||
| Absent | 148 (43.0) | 123 (43.9) | 25 (39.1) | 0.569 | 164 (36.2) | 126 (36.2) | 38 (36.2) | > 0.999 |
| Present | 196 (57.0) | 157 (56.1) | 39 (60.9) | 289 (63.8) | 222 (63.8) | 67 (63.8) | ||
| Lung metastasis | ||||||||
| Absent | 240 (69.8) | 196 (70.0) | 44 (68.8) | 0.964 | 338 (74.6) | 265 (76.1) | 73 (69.5) | 0.172 |
| Present | 104 (30.2) | 84 (30.0) | 20 (31.2) | 115 (25.4) | 83 (23.9) | 32 (30.5) | ||
| Bone metastasis | ||||||||
| Absent | 288 (83.7) | 242 (86.4) | 56 (87.5) | 0.133 | 411 (90.7) | 312 (89.7) | 99 (94.3) | 0.214 |
| Present | 56 (16.3) | 38 (13.6) | 8 (12.5) | 42 (9.3) | 36 (10.3) | 6 (5.7) | ||
| Peritoneal metastasis | ||||||||
| Absent | 265 (77.0) | 221 (78.9) | 44 (68.8) | 0.114 | 345 (76.2) | 263 (75.6) | 82 (78.1) | 0.689 |
| Present | 79 (23.0) | 59 (21.1) | 20 (31.2) | 108 (23.8) | 85 (24.4) | 23 (21.9) | ||
| Lymph node metastasis | ||||||||
| Absent | 215 (62.5) | 171 (61.1) | 44 (68.8) | 0.208 | 268 (59.2) | 205 (58.9) | 63 (60.0) | 0.931 |
| Present | 129 (37.5) | 109 (38.9) | 20 (31.2) | 185 (40.8) | 143 (41.1) | 42 (40.0) | ||